A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents - Concepedia

Concepedia

Publication | Open Access

A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents

DOI Full Paper Access

45

Citations

21

References

2016

Year

Susan D. Mathias, Xiaoyan Li, Melissa Eisen, Nancy Carpenter, Ross D. Crosby, Victor S. Blanchette

Pediatric Blood & Cancer

Abstract

The treatment with romiplostim may be associated with improved HRQoL in children with primary ITP and reduced burden to their parents.

References

	Year	Citations

Page 1